Addition of durvalumab (Dur) upon progression to bevacizumab (Bev) maintenance in advanced HER2-negative (HERNEG) breast cancer (BC): Safety, efficacy and biomarkers
- Quintela-Fandino, M.
- Manso Sànchez, L.M.
- Holgado Martín, E.
- Moreno, M.C.
- Morales Murillo, S.
- Bermejo De Las Heras, B.
- Malon Gimenez, D.
- Colomer Bosch, R.
- Gonzalez Cortijo, L.
- Hornedo, J.
- Mouron, S.
- Muñoz, M.
- Escudero, S.
- Blanco, R.
- Mañes, S.
ISSN: 1569-8041, 0923-7534
Année de publication: 2018
Volumen: 29
Pages: ix24
Type: Article